REGENEREX PHARMA, INC. financial data

Symbol
RGPX on OTC
Location
Las Vegas, NV
Fiscal year end
31 March
Latest financial report
10-Q - Q3 2025 - 17 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5% % 4486%
Debt-to-equity -118% % -0.26%
Return On Equity 69% % 117%
Return On Assets -389% % -113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 282,372,310 shares 1.4%
Common Stock, Shares, Outstanding 281,750,910 shares 1.2%
Entity Public Float $0 USD
Common Stock, Value, Issued $281,751 USD 1.2%
Weighted Average Number of Shares Outstanding, Basic 281,463,410 shares 1.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $136,432 USD
General and Administrative Expense $1,935,014 USD 87%
Operating Income (Loss) $2,733,925 USD -165%
Nonoperating Income (Expense) $468,579 USD -43%
Income Tax Expense (Benefit) $50 USD
Net Income (Loss) Attributable to Parent $3,202,504 USD -136%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $11,659 USD 3866%
Assets, Current $48,429 USD 2539%
Property, Plant and Equipment, Net $5,232 USD
Operating Lease, Right-of-Use Asset $527,235 USD -16%
Assets $617,764 USD -2.4%
Accounts Payable, Current $218,748 USD 41%
Employee-related Liabilities, Current $808,276 USD 15%
Accrued Liabilities, Current $154,357 USD 22%
Liabilities, Current $4,923,680 USD 1.5%
Operating Lease, Liability, Noncurrent $392,884 USD -27%
Liabilities $5,316,564 USD -1.4%
Retained Earnings (Accumulated Deficit) $9,620,486 USD -50%
Stockholders' Equity Attributable to Parent $4,698,800 USD 1.2%
Liabilities and Equity $617,764 USD -2.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $477,943 USD -764%
Net Cash Provided by (Used in) Financing Activities $2,652 USD -105%
Common Stock, Shares Authorized 675,000,000 shares 0%
Common Stock, Shares, Issued 281,750,910 shares 1.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $480,595 USD -129092%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11,659 USD 3866%
Deferred Tax Assets, Valuation Allowance $1,582,654 USD 51%
Depreciation $1,259 USD 10%
Operating Lease, Liability, Current $191,181 USD 15%
Deferred Tax Assets, Operating Loss Carryforwards $921,217 USD 98%
Additional Paid in Capital $4,639,935 USD 236%
Amortization of Intangible Assets $614 USD -79%
Interest Expense $77,866 USD -76%